search
Back to results

REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)

Primary Purpose

Myocardial Infarction

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Intracoronary infusion of enriched bone marrow-derived progenitor cells
Placebo medium supplemented with autologous serum
Sponsored by
A. M. Zeiher
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myocardial Infarction focused on measuring Acute myocardial infarction

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with acute myocardial infarction (ST elevation in at least 2 leads >= 0.2 mV in V1,V2 or V3 or >= 0.1 mV in other leads), treated by one of the following procedures Either acute PCI with stent implantation within 24 hours after symptom onset or treatment with thrombolysis within 12 hours of symptom onset followed by PCI with stent implantation within 24 hours after thrombolysis. Acute PCI / stent implantation has been successful (residual stenosis visually < 30% and TIMI flow >= 2). At the time of inclusion patient does no longer require i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump) Significant regional wall motion abnormality in LV angiogram at the time of acute PCI (ejection fraction <= 45% on visual estimation). Maximal CK elevation >= 400 U/l (measured at 37° C) with significant MB fraction > 6% Age 18 - 80 Years Written informed consent Exclusion Criteria: Regional wall motion abnormality outside the area involved in the index acute myocardial infarction. Need to revascularize additional vessels, outside the infarct artery. Arteriovenous malformations or aneurysms Active infection (CRP > 10 mg/dl) now, or fever or diarrhea within last 4 weeks. Chronic inflammatory disease HIV infection or active hepatitis Neoplastic disease without documented remission within the past 5 years. Cerebrovascular insult within 3 months Impaired renal function (creatinine > 2 mg/dl) at the time of cell therapy Significant liver disease (GOT > 2x upper limit) or spontaneous INR > 1,5) Anemia (hemoglobin < 8.5 mg/dl) Platelet count < 100.000/µl Hypersplenism Known allergy or intolerance to clopidogrel, heparin or abciximab. History of bleeding disorder Gastrointestinal bleeding within 3 months Major surgical procedure or traumata within 2 months Uncontrolled hypertension Pregnancy Mental retardation Previously performed stem / progenitor cell therapy Participation in another clinical trial within the last 30 days.

Sites / Locations

  • Zentralklinik Bad Berka
  • Kerckhoff Klinik
  • Herz- und Diabeteszentrum NRW
  • BG Kliniken Bergmannsheil
  • Klinikum Lippe
  • Rotes-Kreuz Krankenhaus - Kardiologisches Centrum
  • J. W. Goethe University Hospitals
  • Universitätsklinkum Giessen
  • Parxis Schofer, Mathey und Partner
  • Universitätsklikum Homburg
  • Klinikum Kassel
  • Herzzentrum - Universität Leipzig
  • Herzzentrum Ludwigshafen
  • Universitätsklinik Mainz
  • Universitätsklinikum Mannheim
  • Zentralklinikum Suhl
  • Universitätsspital Zürich

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

BMC

Placebo

Arm Description

Intracoronary infusion of autologous bone marrow derived cells

Intracoronary infusion of Placebo medium

Outcomes

Primary Outcome Measures

Change in global left ventricular function in quantitative LV angiography after 4 months.
absolute delta LVEF (%)

Secondary Outcome Measures

Primary endpoint in patients without restenosis.
absolute delta LVEF (%)
Improvement of regional wall motion in infarct area
Reduction of LV end-systolic volume
Major adverse cardiac events (MACE)
Rehospitalization due to heart failure.
NYHA status after 12 months
Amendment for extended follow up after 2 and 5 years:
outcomes in major adverse cardiac events (MACE)
Rehospitalization due to heart failure
NYHA status
patients in MRI subgroup: improvement in left ventricular function

Full Information

First Posted
January 18, 2006
Last Updated
September 19, 2012
Sponsor
A. M. Zeiher
Collaborators
Johann Wolfgang Goethe University Hospital, Blutspendedienst Baden-Württemberg - Hessen, Guidant Corporation, Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT00279175
Brief Title
REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)
Official Title
Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR - AMI)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
April 2004 (undefined)
Primary Completion Date
October 2005 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
A. M. Zeiher
Collaborators
Johann Wolfgang Goethe University Hospital, Blutspendedienst Baden-Württemberg - Hessen, Guidant Corporation, Eli Lilly and Company

4. Oversight

5. Study Description

Brief Summary
Impaired contractile function after a heart attack of the heart is a major cause of "heart failure" limiting quality of life and prognosis, which cannot be prevented even with optimal standard therapy, including immediate balloon/stent dilation of the infarct vessel. The aim of the REPAIR-AMI trial is to investigate whether infusion of progenitor cells into the infarct vessel (after successful reperfusion therapy) may improve left ventricular contractile function compared to placebo therapy. After bone marrow aspiration progenitor cells are enriched via a centrifugation method.
Detailed Description
The study is a double-blind, placebo-controlled, randomized, multicenter trial. Patients after an acute myocardial infarction, undergoing successful reperfusion therapy are included. All patients undergo bone marrow aspiration 3 to 6 days after the infarction. After cell processing, enriched bone marrow-derived progenitor cells or placebo medium is infused direct into the infarct related artery during stop-flow. In addition, a left ventricular angiography is performed. After 4 months left ventricular angiography is repeated. The primary endpoint is the difference in change of left ventricular ejection fraction between the two groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction
Keywords
Acute myocardial infarction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
204 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BMC
Arm Type
Experimental
Arm Description
Intracoronary infusion of autologous bone marrow derived cells
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Intracoronary infusion of Placebo medium
Intervention Type
Biological
Intervention Name(s)
Intracoronary infusion of enriched bone marrow-derived progenitor cells
Intervention Type
Biological
Intervention Name(s)
Placebo medium supplemented with autologous serum
Primary Outcome Measure Information:
Title
Change in global left ventricular function in quantitative LV angiography after 4 months.
Description
absolute delta LVEF (%)
Time Frame
baseline to 4 months
Secondary Outcome Measure Information:
Title
Primary endpoint in patients without restenosis.
Description
absolute delta LVEF (%)
Time Frame
baseline to 4 months
Title
Improvement of regional wall motion in infarct area
Time Frame
baseline to 4 months
Title
Reduction of LV end-systolic volume
Time Frame
baseline to 4 months
Title
Major adverse cardiac events (MACE)
Time Frame
at 4, 12 and 60 months
Title
Rehospitalization due to heart failure.
Time Frame
4, 12, 60 months
Title
NYHA status after 12 months
Time Frame
12 months
Title
Amendment for extended follow up after 2 and 5 years:
Time Frame
24 and 60 months
Title
outcomes in major adverse cardiac events (MACE)
Time Frame
4, 12, 60 months
Title
Rehospitalization due to heart failure
Time Frame
4, 12, 60 months
Title
NYHA status
Time Frame
4, 12, 60 months
Title
patients in MRI subgroup: improvement in left ventricular function
Time Frame
4, 12, 60 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with acute myocardial infarction (ST elevation in at least 2 leads >= 0.2 mV in V1,V2 or V3 or >= 0.1 mV in other leads), treated by one of the following procedures Either acute PCI with stent implantation within 24 hours after symptom onset or treatment with thrombolysis within 12 hours of symptom onset followed by PCI with stent implantation within 24 hours after thrombolysis. Acute PCI / stent implantation has been successful (residual stenosis visually < 30% and TIMI flow >= 2). At the time of inclusion patient does no longer require i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump) Significant regional wall motion abnormality in LV angiogram at the time of acute PCI (ejection fraction <= 45% on visual estimation). Maximal CK elevation >= 400 U/l (measured at 37° C) with significant MB fraction > 6% Age 18 - 80 Years Written informed consent Exclusion Criteria: Regional wall motion abnormality outside the area involved in the index acute myocardial infarction. Need to revascularize additional vessels, outside the infarct artery. Arteriovenous malformations or aneurysms Active infection (CRP > 10 mg/dl) now, or fever or diarrhea within last 4 weeks. Chronic inflammatory disease HIV infection or active hepatitis Neoplastic disease without documented remission within the past 5 years. Cerebrovascular insult within 3 months Impaired renal function (creatinine > 2 mg/dl) at the time of cell therapy Significant liver disease (GOT > 2x upper limit) or spontaneous INR > 1,5) Anemia (hemoglobin < 8.5 mg/dl) Platelet count < 100.000/µl Hypersplenism Known allergy or intolerance to clopidogrel, heparin or abciximab. History of bleeding disorder Gastrointestinal bleeding within 3 months Major surgical procedure or traumata within 2 months Uncontrolled hypertension Pregnancy Mental retardation Previously performed stem / progenitor cell therapy Participation in another clinical trial within the last 30 days.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas M Zeiher, MD
Organizational Affiliation
J. W. Goethe University Hospitals
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Volker Schächinger, MD
Organizational Affiliation
J. W. Goethe University Hopspitals
Official's Role
Study Director
Facility Information:
Facility Name
Zentralklinik Bad Berka
City
Bad Berka
ZIP/Postal Code
99437
Country
Germany
Facility Name
Kerckhoff Klinik
City
Bad Nauheim
ZIP/Postal Code
61231
Country
Germany
Facility Name
Herz- und Diabeteszentrum NRW
City
Bad Oeynhausen
ZIP/Postal Code
32545
Country
Germany
Facility Name
BG Kliniken Bergmannsheil
City
Bochum
ZIP/Postal Code
44789
Country
Germany
Facility Name
Klinikum Lippe
City
Detmold
ZIP/Postal Code
32756
Country
Germany
Facility Name
Rotes-Kreuz Krankenhaus - Kardiologisches Centrum
City
Frankfurt
ZIP/Postal Code
60316
Country
Germany
Facility Name
J. W. Goethe University Hospitals
City
Frankfurt
ZIP/Postal Code
60590
Country
Germany
Facility Name
Universitätsklinkum Giessen
City
Giessen
ZIP/Postal Code
35392
Country
Germany
Facility Name
Parxis Schofer, Mathey und Partner
City
Hamburg
ZIP/Postal Code
22763
Country
Germany
Facility Name
Universitätsklikum Homburg
City
Homburg/Saar
ZIP/Postal Code
66421
Country
Germany
Facility Name
Klinikum Kassel
City
Kassel
ZIP/Postal Code
34125
Country
Germany
Facility Name
Herzzentrum - Universität Leipzig
City
Leipzig
ZIP/Postal Code
04289
Country
Germany
Facility Name
Herzzentrum Ludwigshafen
City
Ludwigshafen
ZIP/Postal Code
67073
Country
Germany
Facility Name
Universitätsklinik Mainz
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Universitätsklinikum Mannheim
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Zentralklinikum Suhl
City
Suhl
ZIP/Postal Code
98527
Country
Germany
Facility Name
Universitätsspital Zürich
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
16501626
Citation
Schachinger V, Tonn T, Dimmeler S, Zeiher AM. Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial. Nat Clin Pract Cardiovasc Med. 2006 Mar;3 Suppl 1:S23-8. doi: 10.1038/ncpcardio0441.
Results Reference
background
PubMed Identifier
16990384
Citation
Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006 Sep 21;355(12):1210-21. doi: 10.1056/NEJMoa060186.
Results Reference
result
PubMed Identifier
17098754
Citation
Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006 Dec;27(23):2775-83. doi: 10.1093/eurheartj/ehl388. Epub 2006 Nov 10.
Results Reference
result
PubMed Identifier
19249426
Citation
Dill T, Schachinger V, Rolf A, Mollmann S, Thiele H, Tillmanns H, Assmus B, Dimmeler S, Zeiher AM, Hamm C. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J. 2009 Mar;157(3):541-7. doi: 10.1016/j.ahj.2008.11.011. Epub 2009 Jan 31.
Results Reference
result
PubMed Identifier
17620510
Citation
Erbs S, Linke A, Schachinger V, Assmus B, Thiele H, Diederich KW, Hoffmann C, Dimmeler S, Tonn T, Hambrecht R, Zeiher AM, Schuler G. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation. 2007 Jul 24;116(4):366-74. doi: 10.1161/CIRCULATIONAHA.106.671545. Epub 2007 Jul 9.
Results Reference
result
PubMed Identifier
19996415
Citation
Assmus B, Rolf A, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Tillmanns H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Tonn T, Dimmeler S, Dill T, Zeiher AM, Schachinger V; REPAIR-AMI Investigators. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 2010 Jan;3(1):89-96. doi: 10.1161/CIRCHEARTFAILURE.108.843243. Epub 2009 Dec 8.
Results Reference
result
PubMed Identifier
21681619
Citation
Rolf A, Assmus B, Schachinger V, Rixe J, Mollmann S, Mollmann H, Dimmeler S, Zeiher AM, Hamm CW, Dill T. Maladaptive hypertrophy after acute myocardial infarction positive effect of bone marrow-derived stem cell therapy on regional remodeling measured by cardiac MRI. Clin Res Cardiol. 2011 Nov;100(11):983-92. doi: 10.1007/s00392-011-0330-3. Epub 2011 Jun 17.
Results Reference
derived
PubMed Identifier
20338501
Citation
Assmus B, Tonn T, Seeger FH, Yoon CH, Leistner D, Klotsche J, Schachinger V, Seifried E, Zeiher AM, Dimmeler S. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol. 2010 Mar 30;55(13):1385-94. doi: 10.1016/j.jacc.2009.10.059.
Results Reference
derived

Learn more about this trial

REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)

We'll reach out to this number within 24 hrs